IMNN

Imunon, Inc.
CAPPED RATING

Imunon, Inc. (IMNN) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (F). The rating has held at D+ for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.8 / 5.0
D+
Value
C+
Factor Score 2.5 / 5.0
Growth
C
Factor Score 2.3 / 5.0
Profitability
F
Factor Score 0.6 / 5.0
Momentum
D-
Factor Score 0.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.4
EV / EBITDA -0.5
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -54.4%
Price Return 12M -80.8%
Catalyst Signal 0.00
Market Cap $4.0M
TTM Revenue N/A
Price / Sales N/A
ROE -429.7%

Historical Factor Score Progression

Held D+ for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.5) C (2.3) F (0.6) D- (0.9) C+ (2.6) D+ (1.8)
2026-11-05 C+ (2.5) C (2.2) F (0.7) D- (1.1) C+ (2.7) D+ (1.8)
2026-10-29 C+ (2.5) C (2.2) F (0.7) D- (1.0) C+ (2.7) D+ (1.8)
2026-10-22 C+ (2.5) C (2.2) F (0.6) D (1.4) C+ (2.6) C- (1.9)
2026-10-15 C+ (2.5) C (2.2) F (0.6) D- (1.0) C+ (2.6) D+ (1.8)
Page 1 of 4